Body fluid biomarkers for multiple sclerosis--the long road to clinical application (Q38590773)

4 September 2017

title

Body fluid biomarkers for multiple sclerosis--the long road to clinical application (English)

1 reference

4 September 2017

0 references

0 references

1

Charlotte E Teunissen

1 reference

4 September 2017

5

Joep Killestein

1 reference

4 September 2017

Arjan Malekzadeh

2

1 reference

4 September 2017

Cyra Leurs

series ordinal

3

1 reference

4 September 2017

Claire Bridel

series ordinal

4

1 reference

4 September 2017

language of work or name

English

0 references

publication date

22 September 2015

1 reference

4 September 2017

published in

Nature Reviews Neurology

1 reference

4 September 2017

volume

11

1 reference

4 September 2017

issue

10

1 reference

4 September 2017

page(s)

585-596

1 reference

The utility of cerebrospinal fluid analysis in patients with multiple sclerosis

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Body fluid biomarkers in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Defining the clinical course of multiple sclerosis: the 2013 revisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Intrathecal oligoclonal IgG synthesis in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Association of genetic markers with CSF oligoclonal bands in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

The diagnostic significance of antibody specificity indices in multiple sclerosis and herpes virus induced diseases of the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Elevated antibody reactivity to measles virus NCORE protein among patients with multiple sclerosis and their healthy siblings with intrathecal oligoclonal immunoglobulin G production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Measles IgG antibody index correlates with T2 lesion load on MRI in patients with early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Intrathecal, polyspecific antiviral immune response in oligoclonal band negative multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Free light chain monomer-dimer patterns in the diagnosis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Detection of oligoclonal free kappa chains in the absence of oligoclonal IgG in the CSF of patients with suspected multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Kappa free light chains: diagnostic and prognostic relevance in MS and CIS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Potassium channel KIR4.1 as an immune target in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Potassium channel KIR4.1-specific antibodies in children with acquired demyelinating CNS disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

The spectrum of MOG autoantibody-associated demyelinating diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Antimyelin antibodies as predictors of disability after clinically isolated syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

The evidence for a role of B cells in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

CHI3L1 plays a role in cancer through enhanced production of pro-inflammatory/pro-tumorigenic and angiogenic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Novel methylxanthine derivative-mediated anti-inflammatory effects in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Circulating microRNAs involved in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Elevated neurofilament levels in neurological diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Serum and cerebrospinal fluid heavy neurofilaments and antibodies against them in early multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Neuromyelitis optica is distinct from multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Neuromyelitis optica (Devic's syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Relationship between NMO-antibody and anti-MOG antibody in optic neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Haptoglobin, inflammation and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Proteome analysis of haptoglobin in cerebrospinal fluid of neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Analyses of haptoglobin level in the cerebrospinal fluid and serum of patients with neuromyelitis optica and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

NLRP3 inflammasome activity is negatively controlled by miR-223.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

MicroRNA-15b promotes neurogenesis and inhibits neural progenitor proliferation by directly repressing TET3 during early neocortical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Circulating microRNAs as biomarkers for disease staging in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Increased neurofilament light chain blood levels in neurodegenerative neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Antibody dissociation rates are predictive of neutralizing antibody (NAb) course: A comparison of interferon beta-1b-treated Multiple Sclerosis (MS) patients with transient versus sustained NAbs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Characterization of anti-natalizumab antibodies in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Interleukin 17F level and interferon β response in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

MicroRNA expression changes during interferon-beta treatment in the peripheral blood of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Biomarker studies in multiple sclerosis: from proteins to noncoding RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Biobanking of CSF: international standardization to optimize biomarker development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Multiple sclerosis genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

New multiple sclerosis phenotypic classification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Influence of oligoclonal IgM specificity in multiple sclerosis disease course

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

The intrathecal, polyspecific antiviral immune response: Specific for MS or a general marker of CNS autoimmunity?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Free light chain monomers in the diagnosis of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Quantification of immunoglobulin free light chains in cerebrospinal fluid by nephelometry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Collateral benefit: the comeback of MOG antibodies as a biomarker in neurological practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Neurofilament and glial fibrillary acidic protein in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

A comparative study of CSF neurofilament light and heavy chain protein in MS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Neuromyelitis optica: a positive appraisal of seronegative cases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Increased anti-KIR4.1 antibodies in multiple sclerosis: could it be a marker of disease relapse?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Proteomics comparison of the sera from multiple sclerosis patients and neuromyelitis optica patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Intrathecal synthesis in particular types of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Neurofilament light as a prognostic marker in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

A Practical Guide to Immunoassay Method Validation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2015.173

Proteome analysis of biomarkers in the cerebrospinal fluid of neuromyelitis optica patients.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26392381

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Biological markers in CSF and blood for axonal degeneration in multiple sclerosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26392381

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRNEUROL.2015.173

1 reference

Dimensions Publication ID

4 September 2017

1007812072

0 references

1 reference